EGFR and lung cancer: In addition, an in vitro cell model of acquired resistance to osimertinib was established in EGFR mutant lung cancer HCC827 cells (HCC827OR), the IC50 values of which were over 500-fold higher than those of the parental cells (Figure 6F).